BioAge Labs, Inc. BIOA 深 沪
已收盘 02-06 16:00:00 美东时间
20.73
+0.750
+3.75%
华盛通- 最 高21.17
- 今 开20.22
- 成交量 83.80万股
- 最 低 19.54
- 昨 收 19.98
- 总市值 8.66亿
- 52周最高 24.00
- 市盈率 静 --
- 换手率 2.01%
- 52周最低 2.88
- 委 比 -63.24%
- 总股本 4175.25万
- 历史最高 26.62
- 量 比 1.33
- 振 幅 8.16%
- 历史最低 0.156
- 每 手 1
- 风险率 4.55%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 瑞穗上调希捷科技、西部数据、CoreWeave目标价；Trade Desk、W.R. Berkley遭多家大行下调目标价
今日重点评级关注：瑞穗：维持Syndax制药"跑赢大市"评级，目标价从410美元升至600美元；HC Wainwright & Co.：维持60 Degrees Pharmaceuticals, Inc."买入"评级，目标价从6美元升至24美元
01-28 10:59
BioAge Labs Announces Up To $75M Common Stock Offering
BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge", "the Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today
01-21 05:14
BioAge Labs Expands BGE-102 Development Program Into Ophthalmology, With Initial Proof-Of-Concept Study In Patients With Diabetic Macular Edema
BGE-102 has the potential for therapeutic retinal exposure with oral delivery, reducing treatment burden in ocular indications currently treated with intravitreal therapiesGrowing preclinical and clinical evidence points
01-20 22:07
美股牛股 | 娱乐集团TryHard单日狂升138%！Moderna大涨17%，业绩指引超预期
双重利好催化！娱乐集团TryHard单日狂升138%；Moderna股价大涨17%，业绩指引超预期，预计2026年实现10%收入增长>>
01-14 14:20
美股牛股 | 私人航空公司UP单日暴涨46%！One Stop大涨29%，获美军预生产订单
私人航空公司UP单日暴涨46%！One Stop股价涨29%，获美军预生产订单；BIOA涨逾27%，核心在研药获突破进展>>
01-13 17:24
Why Penguin Solutions Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket
Shares of Penguin Solutions Inc (NASDAQ:PENG) rose sharply in pre-market tradin...
01-07 18:36
Dynavax Technologies, Omeros, Agios Pharmaceuticals, Nike And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones index gaining around 200 points on ...
2025-12-25 00:06
美股大行评级 | 潜在涨幅2566.67%！Ascendiant Capital上调GRI Bio目标价至36美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从35美元升至36美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.75美元升至8美元
2025-12-09 10:32
BioAge Labs Data From BGE-102 Study Shows Well-Tolerance, Strong Target Engagement In Patients With Cardiovascular Risk Factors
BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced positive
2025-12-04 22:06
Bioage Labs Q3 EPS $(0.56) Beats $(0.58) Estimate, Sales $2.054M
Bioage Labs (NASDAQ:BIOA) reported quarterly losses of $(0.56) per share which beat the analyst consensus estimate of $(0.58) by 3.45 percent. This is a 91.64 percent increase over losses of $(6.70) per share from the
2025-11-07 06:05
